📊 NEUP Key Takeaways
Is Neuphoria Therapeutics Inc. (NEUP) a Good Investment?
Neuphoria Therapeutics is a pre-commercial biotech company burning cash at $13.6M annually against minimal revenue of $15.6M, resulting in severe negative margins (-69.8% operating, -54.6% net). With $19.4M cash reserves, the company has approximately 1.4 years of runway at current burn rates, requiring immediate revenue acceleration or cost restructuring to avoid dilutive financing or insolvency.
Neuphoria shows strong liquidity and zero leverage, providing roughly two years of runway to fund operations while revenue has begun to materialize. However, profitability remains deeply negative with sizable operating and free cash outflows, and revenue growth visibility is unclear. Maintain a neutral stance pending evidence of sustained top-line growth and margin improvement.
Neuphoria Therapeutics Inc. Key Strengths (NEUP)
- Strong cash position of $19.4M with zero long-term debt and minimal liabilities ($5.4M)
- Excellent liquidity metrics (14.31x current/quick ratio) providing near-term solvency cushion
- EPS loss narrowing with 98.8% YoY improvement indicating trajectory toward profitability
- Robust cash position and 9.0x current ratio
- No long-term debt and low liabilities
- EPS improved materially YoY despite losses
NEUP Stock Risks: Neuphoria Therapeutics Inc. Investment Risks
- Severe cash burn ($13.6M annually) against $15.6M revenue implies only 1.4 year runway without growth or cost control
- Deeply unprofitable operations with -69.8% operating margin and business model not yet validated at scale
- Binary pharma execution risk: success dependent on clinical trial outcomes and FDA approvals with no near-term visibility
- Negative returns destroying shareholder value (ROE -29%, ROA -24.6%)
- Pre-commercial revenue model with operating expenses far exceeding top-line generation
- No insider trading activity in 90 days may signal restricted trading window or limited confidence
- Sustained negative free cash flow and cash burn
- Unclear revenue trajectory and gross margin visibility
- Potential need for future equity financing if burn persists
Key Metrics to Watch
- Quarterly revenue growth and path to gross margin expansion on any approved products
- Operating cash burn rate trend and extension of cash runway beyond current 1.4 year horizon
- Clinical trial progress milestones and FDA approval timelines for pipeline assets
- Gross margin achievement on commercial products (critical for operating profitability)
- Capital raise announcements and dilution impact on shareholder equity
- Operating cash flow (burn) and cash runway
- Revenue growth YoY and operating margin trend
Neuphoria Therapeutics Inc. (NEUP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.31x current ratio provides a solid financial cushion.
NEUP Profit Margin, ROE & Profitability Analysis
NEUP vs Healthcare Sector: How Neuphoria Therapeutics Inc. Compares
How Neuphoria Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Neuphoria Therapeutics Inc. Stock Overvalued? NEUP Valuation Analysis 2026
Based on fundamental analysis, Neuphoria Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Neuphoria Therapeutics Inc. Balance Sheet: NEUP Debt, Cash & Liquidity
NEUP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Neuphoria Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-18.62 indicates the company is currently unprofitable.
NEUP Revenue Growth, EPS Growth & YoY Performance
NEUP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $15.0M | -$505.1K | $-0.09 |
| Q3 2025 | $15.0M | -$804.8K | $-2.83 |
| Q2 2025 | $662.7K | -$804.8K | $-0.77 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Neuphoria Therapeutics Inc. Dividends, Buybacks & Capital Allocation
NEUP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Neuphoria Therapeutics Inc. (CIK: 0001191070)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NEUP
What is the AI rating for NEUP?
Neuphoria Therapeutics Inc. (NEUP) has a Combined AI Grade of C from Claude (D) and ChatGPT (B) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NEUP's key strengths?
Claude: Strong cash position of $19.4M with zero long-term debt and minimal liabilities ($5.4M). Excellent liquidity metrics (14.31x current/quick ratio) providing near-term solvency cushion. ChatGPT: Robust cash position and 9.0x current ratio. No long-term debt and low liabilities.
What are the risks of investing in NEUP?
Claude: Severe cash burn ($13.6M annually) against $15.6M revenue implies only 1.4 year runway without growth or cost control. Deeply unprofitable operations with -69.8% operating margin and business model not yet validated at scale. ChatGPT: Sustained negative free cash flow and cash burn. Unclear revenue trajectory and gross margin visibility.
What is NEUP's revenue and growth?
Neuphoria Therapeutics Inc. reported revenue of $15.6M.
Does NEUP pay dividends?
Neuphoria Therapeutics Inc. does not currently pay dividends.
Where can I find NEUP SEC filings?
Official SEC filings for Neuphoria Therapeutics Inc. (CIK: 0001191070) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NEUP's EPS?
Neuphoria Therapeutics Inc. has a diluted EPS of $-2.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NEUP's fundamental grade?
Based on our AI fundamental analysis in May 2026, Neuphoria Therapeutics Inc. has a C grade with 76% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NEUP stock overvalued or undervalued?
Valuation metrics for NEUP: ROE of -29.0% (sector avg: 15%), net margin of -54.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NEUP's AI grade for 2026?
Our dual AI analysis gives Neuphoria Therapeutics Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NEUP's free cash flow?
Neuphoria Therapeutics Inc.'s operating cash flow is $-13.6M, with capital expenditures of N/A. FCF margin is -86.7%.
How does NEUP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -54.6% (avg: 12%), ROE -29.0% (avg: 15%), current ratio 14.31 (avg: 2).